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Pulmonary metastasetomy is known to be able to improve the survival 
in selected patients with metastatic lung disease. We analyzed the short 
term treatment results of simultaneous multitarget irradiation using 
tomotherapy in the primary or secondary lung cancer patients to know 
whether radiation therapy could substitute pulmonary operation. We 
treated thirty two patients using tomotherapy for 1 year after our ma-
chine installation in 2005. The original malignancies were hepatocel-
luar carcinoma, lung cancer, breast cancer, colorectal cancer, invasive 
thymoma, thyroid cancer, pancreas cancer, endometrial cancer, renal 
cell carcinoma, oral cavity cancer and Ewing’s sarcoma. The average 
number of pulmonary targets was 5.1 (range: 1-15). The unilateral pul-
monary lesions were in eleven patients (34.4%) and bilateral lesions in 
21 patients (65.6%). In 12 patients (37.5%), synchronous extrapulmo-
nary targets were present. Twenty six patients (81.3%) had been treated 
with chemotherapy for pulmonary metastasis before tomotherapy. The 
median number of cycles of systemic chemotherapy was nine (range 
1- 21) and the median interval between chemotherapy and tomotherapy 
was 2 months (range: 1-36 months). Four patients (12.5%) had a past 
history of mediastinal radiotherapy. We immobilized the patients with 
BodyFix system (Medical Intelligence, Germany) and deﬁned the 
GTV (gross tumor volume) and PTV (planning target volume: GTV + 
0.5 ~ 1.5cm) in chest CT scan and their median doses were 50.0±5.99 
Gy and 40.0±7.03 Gy with 3-20 fractionations, respectively. Median 
treatment duration was 14days (range: 3-28 days). Before treatment, we 
always conﬁrmed the positions of the targets and the isodose distri-
bution after checking megavoltage CT scan. To decrease the risk of 
pulmonary toxicity, we tried to decrease the values of mean lung dose, 
median lung dose and V25 as low as possible. RECIST (Response 
Evaluation Criteria In Solid Tumors) method and CTCAE (Common 
Terminology Criteria for Adverse Event) method were used to evaluate 
the post-treatment response and pulmonary toxicity. The number of 
eligible patients was thirty (93.8%) whom we could follow up more 
than 1 month. Median follow up period was 6 month (1-13 months). 
The rates of complete and partial response were 3.3% and 46.7% in 1 
month and 15.6% and 36.7% in 3 months after treatment. The over-
all response rate was 52.3% in 3 months after treatment. The data of 
pulmonary dosimetric analysis were that in right and left lung, mean 
lung doses were 13.89±6.70 Gy and 15.20±5.44 Gy, median lung doses 
were 12.52±6.27 Gy and 13.43±6.00 Gy and the values of V25 were 
13.76±10.04% and 15.25±8.77%. Radiation pneumonitis or pulmonary 
ﬁbrosis was appeared in 10 patients (33.3%) but all pulmonary toxici-
ties were less than grade III. We can suggest that tomotherapy for mul-
tiple lung metastasis was a safe and effective treatment modality but we 
need study about further analysis of survivals, chronic complications 
and inﬂuencing factors through long term follow up in larger group of 
patients to make up the limitation of our experience.
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Rationale: Pleural effusions have classically been divided into transu-
dates and exudates. If it is exudative, more diagnostic tests are required 
in order to determine the cause of the local disease. Malignancy is a 
common and important cause of exudative pleural effusions. Because 
pleural ﬂuid cytology and pleural biopsy specimens do not provide a 
diagnosis in a high percentage of malignant effusions, several tumor 
markers have been studied. To overcome this limitation, we hypoth-
esized that measurement of melanoma antigen gene (MAGE) would be 
useful in differentiating between benign and malignant effusion. 
Methods: We studied prospectively 127 consecutive patients with 
pleural effusion (malignant 42, tuberculous 27, parapneumonic 17, 
empyema 5, transudative 21, miscellaneous 3, nondiagnostic 12). We 
examined standard parameters of pleural effusion and measured the 
expression of MAGE and cytology with the obtained pleural effusion. 
Expression of MAGE was interpreted by means of a commercial kit 
using RT-PCR method. 
Results: The sensitivity and speciﬁcity of cytology were 45.2% and 
100% respectively and the positive predictive value and negative pre-
dictive value of cytology were also 100% and 76.0% respectively. The 
sensitivity and speciﬁcity of MAGE were 27.0% and 98.5% respec-
tively and the positive predictive value and negative predictive value of 
MAGE were also 90.9% and 71.3% respectively. Using the cutoff value 
of 3 μg/L for CEA, the combination of MAGE and CEA in pleural 
ﬂuid revealed 71.4% sensitivity and 89.0% speciﬁcity in diagnosis of 
malignant pleural effusion. 
Conclusions: The ﬁndings of this study suggest that the combination 
of MAGE and CEA in addition with pleural ﬂuid cytology would be 
useful as a diagnostic marker in differentiating between benign and 
malignant pleural effusion.
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Introduction: Few patients with malignant pleural mesothelioma 
(MPM) are candidates for surgical treatment. Since it is almost impos-
sible to achieve a R0-resection, surgery has been combined with other 
treatment modalities. In this retrospective study, the results of surgical 
therapy as part of two different therapeutic regimens were investigated. 
Materials and Methods: Between 2002 and 2005, 15 MPM patients 
were treated with ExtraPleural Pneumonectomy (EPP/TRT) and 
postoperative hemi-Thoracic RadioTherapy (54 Gy). Previously (1999-
2001), 20 patients underwent a combination of cytoreductive surgery 
- pleurectomy (12) or EPP (8) - and Hyperthermic IntraTHOracic 
Chemotherapy (HITHOC) with cisplatin and doxorubicin, followed by 
radiotherapy to the thoracotomy scar and drainage tracts (24 Gy). 
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Results: The two groups were comparable regarding age, sex, per-
formance status, pulmonary function, and tumor histology. Median 
duration of follow-up was 16 (5-59) months for patients treated with 
EPP/TRT and 12 (3-65) months for patients treated with HITHOC. In 
the EPP/TRT-group, the median operative time was 5.3 (3-7) hours vs. 
the HITHOC-group 6.9 (5-9) hours (p<0.0001). There was no dif-
ference in the duration of postoperative hospital stay. Postoperative 
complications occurred in 8 patients (53%) treated with EPP/TRT and 
in 14 patients (70%) treated with HITHOC. Surgical reintervention 
consisted of correction of diaphragmatic rupture, bronchopleural ﬁstula 
or empyema in. Two HITHOC-patients died following a massive bleed-
ing from an open pleural cavity with a Clagett window. 
Recurrent disease developed in 11 patients (73%) treated with EPP/
TRT and in 18 patients (90%) treated with HITHOC. Median disease-
free survival was 21 vs. 8 months (p=0.03). In the EPP/TRT-group, lo-
coregional recurrence occurred in 5 patients as compared to 16 patients 
in the HITHOC-group (43% versus 86%; p=0.009). Median overall 
survival was 29 vs.11 months (p=0.08).
Discussion: Surgical treatment of malignant pleural mesothelioma 
is accompanied by a high rate of (surgical) complications. Results of 
surgical resection with adjuvant radiotherapy of the hemithorax are 
more encouraging than those of cytoreduction with intraoperative 
chemoperfusion. A European phase-II study (EORTC protocol 08031) 
has been initiated to assess the feasibility of induction chemotherapy 
followed by extrapleural pneumonectomy and postoperative hemitho-
racic radiotherapy.
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Novel strategies in molecular targeted therapy of mesothelioma
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Background: The number of patients with malignant mesothelioma 
is expected to increase in the industrialized world within the next 
years. Although few anticancer drugs like gemcitabine, pemetrexed 
and cisplatin have shown proven activity in this speciﬁc tumor entity, 
overall survival following systemic therapy is still unsatisfactory. New 
therapeutic strategies are urgently needed. 
In a well characterized mesothelioma cell-line model we have analyzed 
the in-vitro cytotoxic activity of several novel molecular targeting 
agents.
Methods And Materials: Individual mesothelioma cell-lines (MSTO-
211H, NCI- H2052, NCI-H2452, NCI-H28) were exposed to several 
novel molecular targeting agents. Cellular growth was evaluated by 
MTT assay. The molecular proﬁle of the cell-line model was character-
ized by immunoblotting, immunocytochemistry and DNA-microarray 
with the intention to detect target structures for the novel agents. 
Results: 17-AAG - an inhibitor of HSP90 - and Bortezomib - a pro-
teasom inhibitor - were found to be the most effective agents among 
the panel of compounds and drugs we have tested so far. For 17-AAG 
we have observed IC50 values < 1 μM. For Bortezomib we have 
observed IC50 values between 0,002 and 0,01 μM. A strong expression 
of HSP90 and its client proteins EGFR,VEGFR2, c-met and Akt was 
detected in majority of the cell-lines. 
Conclusion: Our results indicate that 17-AAG and bortezomib are 
inhibiting the growth of mesothelioma cell-lines in vitro. Our ﬁndings 
in this model demonstrate some evidence, that mesothelioma represents 
a molecular proﬁle that is vulnerable for targeting HSP90. We are also 
continuing to analyse the molecular mechanisms behind the high ef-
ﬁcacy of bortezomib against mesothelioma cell-lines. Currently, we are 
combining both drugs in different sequences and dose level in our in 
vitro-experiments.
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A 15-year review of outcomes at The Ottawa Hospital Regional 
Cancer Centre [TOHRCC] of the treatment of malignant pleural 
mesothelioma [MPM], with a case-control analysis of the role of 
radical surgery
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Background: Most patients with MPM present with advanced disease 
and are most often treated palliatively with platinum-based chemother-
apy. Occasional patients are diagnosed at an earlier stage, with minimal 
pleural thickening. Some have advocated aggressive, multimodality 
therapy that includes radical resections such as extrapleural pneumo-
nectomy [EPP] in such patients. While phase II trials of EPP suggest 
improved outcomes, debate remains as to its overall role in the manage-
ment of MPM, as there are no randomized trials of EPP versus less 
intensive treatment strategies.
Methods: Records of all patients with MPM treated at TOHRCC from 
1991-2005 were reviewed. Data abstracted included dates of diagnosis, 
death or last follow-up, symptoms at presentation, staging, treatments 
and outcomes, and known baseline prognostic variables (age, gender, 
stage, histologic subtype, performance status [PS], weight loss, hemo-
globin, white blood cell [WBC] and platelet counts) were recorded. 
Cox regression analyses were performed to identify factors associated 
with survival. Additionally, for each patient who underwent radical sur-
gery (n=15), a control, not undergoing EPP but matched for previously 
identiﬁed prognostic variables, was identiﬁed.
Results: The median survival [MS] time of all 147 included patients 
was 7.7 months and for those patients with PS 0-1 was 13.8 months. By 
univariate analysis, factors associated with a worse prognosis included 
poor PS, higher TNM stage, age, >5% weight loss, WBC count >8.3 
x106/L, and platelet count >350 x109/L. Stage, weight loss, PS, and 
platelet count remained independently associated by multivariate analy-
sis. No trends in outcomes over time were identiﬁed, although EPP 
has only been performed at TOHRCC since 1996. Patients undergoing 
EPP were younger (p=0.008), had a better PS (p=0.018) and a higher 
baseline hemoglobin (p=0.026). MS of EPP patients was 25.4 months 
(95%CI 12.2-43.6), which was signiﬁcantly prolonged compared to 
all other patients (p=0.0007); however, when controlled for confound-
ing factors with multivariate Cox regression analysis, this difference 
was no longer signiﬁcant (p=0.11). Comparison of EPP patients with 
matched case-controls showed a trend towards improved survival 
(p=0.07) (see graph). 
Conclusions: This analysis conﬁrms that the baseline prognostic 
factors determined in clinical trials are also applicable to the general 
